IL6 and atherosclerosis: IL-1β has not been studied as a biomarker for cardiovascular disease because unlike hsCRP and IL-6, it is difficult to directly measure its levels in the plasma; nevertheless, many studies have been conducted to examine its role as a therapeutic target in atherosclerosis [79].